A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative treatment for multiple myeloma (MM); however, due to high-treatment related mortality (TRM) its role is not well defined. METHODS: Patients with newly diagnosed, relapsed, or primary refractory myelom...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Bashir, Qaiser, Khan, Hassan, Thall, Peter F, Liu, Ping, Shah, Nina, Kebriaei, Partow, Parmar, Simrit, Oran, Betul, Ciurea, Stefan, Nieto, Yago, Jones, Roy, Hosing, Chitra M, Popat, Uday R, Dinh, Yvonne T, Rondon, Gabriela, Orlowski, Robert Z., Shah, Jatin J, De Lima, Marcos, Shpall, Elizabeth, Champlin, Richard, Giralt, Sergio, Qazilbash, Muzaffar
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157818/
https://ncbi.nlm.nih.gov/pubmed/23872222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.07.008
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi